Classen Immunotherapies, Inc. v. Biogen Idec

Federal Circuit

Classen Immunotherapies, Inc. v. Biogen Idec

178 F. App'x 14

CourtCourt of Appeals for the Federal Circuit

DecidedApril 10, 2006

DocketNo. 2006-1216

StatusPublished

This text of 178 F. App'x 14 (Classen Immunotherapies, Inc. v. Biogen Idec) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Classen Immunotherapies, Inc. v. Biogen Idec, 178 F. App'x 14 (Fed. Cir. 2006).

Pincite

Opinion

ON MOTION

MICHEL, Chief Judge.

ORDER

GlaxoSmithKline (GSK) moves to dismiss this appeal, from the United States District Court for the District of Maryland in 04-CV-02607, for lack of jurisdiction. GSK also moves for fees and costs. Clas-sen Immunotherapies, Inc. submits an opposition, out of time. GSK replies.

Classen sued the defendants for infringement. The district court granted motions to dismiss certain counts of Clas-sen’s complaint and granted Merck & Co., Inc.’s motion for summary judgment of noninfringement. However, Merck’s counterclaim for a declaratory judgment of invalidity remains pending and, indeed, a trial date has been set. Thus, there is no final judgment and any appeal is premature. Nystrom v. TREX Co., Inc., 339 F.3d 1347 (Fed.Cir.2003).

Accordingly,

IT IS ORDERED THAT:

(1) The motion to dismiss is granted.

(2) The motion for fees is denied.

(3) Costs awarded to GSK.

Free access — add to your briefcase to read the full text and ask questions with AI